Refine your search

Search Results within category "Children's Health"

Search all categories
Study matches: 22

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.


Integrating AAT into TF-CBT for Maltreated Youth: A Randomized Feasibility Trial

This is a randomized clinical trial designed to test the feasibility of integrating Animal-Assisted Therapy (AAT) into standard Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for the treatment of posttraumatic stress and associated symptoms of maltreated youth.
Allen -ballen1@pennstatehealth.psu.edu
All
Younger than 18 year(s) old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Child between the ages of 6 and 17
Child has a history of physical abuse, sexual abuse, or other type of maltreatment
Child displays posttraumatic stress symptoms
Primary caregiver willing to participate in treatment
Exclusion Criteria:
Child has a developmental or intellectual delay.
Uncontrolled allergy to or fear of dogs on part of either the child or caregiver.
CHild or caregiver has a history of aggression toward animals
Show full eligibility criteria
NCT03135119
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Harrisburg, PA

A Phase I/II, Multicenter, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric And Young Adult Patients with Previously Treated Solid Tumors

A study of the safety and effectiveness of cobimetinib in patients with previously treated solid tumors.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
Younger than 18 year(s) old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
A solid tumor that has not responded to previous treatment.
Age must be 6 months or older to younger than 18 years of age.
Disease must be measurable by accepted tests.
Availability of tumor tissue at study enrollment is mandatory.
Exclusion Criteria:
Prior treatment with cobimetinib or other similar drug.
Treatment with high-dose chemotherapy and stem-cell rescue within 3 months prior to the study.
Show full eligibility criteria
NCT02639546
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia

A study of the safety and efficacy of ruxolitinib with routine chemotherapy for children with leukemia with specific genetic changes.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
A diagnosis of leukemia, specifically de novo high B-ALL with eligible genetic changes.
Age must be greater than 1 year old and less than or equal to 21 years old at leukemia diagnosis.
Have completed an acceptable induction therapy either on study or by hospital standard of care.
Exclusion Criteria:
Had any other chemotherapy before induction therapy, with exceptions.
Down Syndrome.
Show full eligibility criteria
NCT02723994
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who Have Failed to Respond to Steroid Treatment for Acute GVHD

A study of the safety and effectiveness of remestemcel-L in pediatric subjects with acute Graft versus Host Disease (aGVHD) following transplant (HSCT) that has failed to respond to steroid treatment.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
Younger than 18 year(s) old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
A diagnosis of acute GVHD.
2 months of age and older to under 18 years of age.
Patient has failed to respond to steroid treatment.
Exclusion Criteria:
Has had any second line therapy to treat aGVHD.
Severe hepatic veno-occlusive disease (VOD).
Show full eligibility criteria
NCT02336230
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Joint Intervention for Behavior and Sleep in School aged Children (JIBS)

It is well known that many children with ADHD also have problems sleeping and that not getting enough sleep can make a child’s behavior worse. This research is being done to find out how to best treat children with both behavior and sleep problems. Parents will complete assessments of their child's behaviors and sleeping patterns and attend 4 therapy sessions that assist with problematic behaviors in their child.
Mills -smills1@pennstatehealth.psu.edu
All
Younger than 18 year(s) old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Ages 5-10 years
Diagnosis of ADHD, Conduct Disorder, and/or Oppositional Defiant Disorder
Difficulty falling or staying asleep
Exclusion Criteria:
Diagnosis of an intellectual disability, psychosis, Autism, or a pervasive developmental disorder
Diagnosis of sleep disordered breathing (e.g. sleep apnea) or other medical condition (e.g. asthma)
Use of anti-psychotic medications
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Mobile Eye-tracking as a Tool for Studying Socioemotional Development: Threat-related Attention in Social Context

This is cross-sectional correlational study in 5- to 6-year-olds comparing threat-related attention assessed in screen-based and naturalistic contexts by using stationary and mobile eye tracking respectively.
Fu -xuf104@psu.edu
All
Younger than 18 year(s) old
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Between five to six years of age
Speak English
No Gross developmental delays or serious neurological illnesses
Have been born within three weeks of due date
Weighed more than approximately five pounds at birth
Exclusion Criteria:
Outside of the age range of 5-6 years
Have gross developmental delays or serious neurological illnesses
Weighed less than 5 pounds at birth
Have not been born within three weeks of their due date
Do not speak English
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy followed by maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma

A study of the safety and feasibility of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in patients with newly diagnosed high risk neuroblastoma.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
A confirmed diagnosis of neuroblastoma.
Must be 21 years of age or younger when diagnosed.
No prior systemic therapy with some exceptions.
Tumor samples will be obtained only in a non-significant risk manner and not solely for the purpose of the study.
Exclusion Criteria:
Receiving another study drug while on this study.
Female patients who are lactating are not eligible unless they agree not toe breast feed.
Show full eligibility criteria
NCT02559778
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Multicenter, Single-Arm, Open- Label Study To Evaluate The Activity, Safety and Pharmacokinetics Of Lenalidomide (Revlimid) in Pediatric Subjects from 1 To = 18 Years of Age with Relapsed Or Refractory Acute Myeloid Leukemia

A study of the safety and effectiveness of lenalidomide for pediatric leukemia (AML) that has returned or is not responding to treatment.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
A diagnosis of acute myeloid leukemia (AML) that has returned or not responded to treatment.
One year of age up to and including 18 years of age.
Has recovered from the effects of previous treatment.
Exclusion Criteria:
Down syndrome.
Subject has had prior treatment with lenalidomide.
Show full eligibility criteria
NCT02538965
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma and Medulloblastoma

A study if the safety and effectiveness of nifurtimox in children with neuroblastoma or medulloblastoma, that has returned or is not responding to treatment.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Ages 0-21 years at the time of diagnosis.
Diagnosis of neuroblastoma or medulloblastoma.
Disease has not responded to previous treatment.
Disease is measurable bu accepted tests.
Exclusion Criteria:
Patients who weigh less than 3.5 kg (7.7 lbs).
Currently receiving another study drug.
Currently receiving other anticancer agents.
Show full eligibility criteria
NCT00601003
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study

Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
Beiler -jbeiler@pennstatehealth.psu.edu
All
All
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Healthy mom and baby pairs delivering at HMC
Full term baby (36 weeks)
Following at an HMC practice for infant care
English speaking
Exclusion Criteria:
Low birth weight (<2250g)
Medical issues for mom or baby that prevent routine newborn care
Plan for newborn to be adopted
Plan to move out of Central PA within 1 year
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Phase I Study of Carfilzomib in combination with Cyclophosphamide and Etoposide for Children with Relapsed or Refractory Solid Tumors and Leukemias

A study of the safety of carfilzomib for children with solid tumors and leukemias that returned or did not respond to previous treatment.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of relapsed or refractory leukemia or solid timor.
Age 6 months to less than 30 years at enrollment.
Must be fully recovered from effects of previous treatment.
Life expectancy greater than or equal to 3 months.
Exclusion Criteria:
Prior treatment with carfilzomib.
Known allergy to Captisol®.
Down syndrome.
Show full eligibility criteria
NCT02512926
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant

A study to confirm and expand information on safety and effectiveness of defibrotide compared to best standard care to prevent veno-occlusive disease of the liver in adult and pediatric transplant patients. This is a randomized study so patients will be selected by chance to be in either the group that receives defibrotide or the group that does not receive defibrotide.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
Younger than 18 year(s) old
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Must be older than 1 month of age.
Scheduled for a stem cell transplant and be at high risk of veno-occlusive disease.
Be at high risk of veno-occlusive disease.
Exclusion Criteria:
Unstable blood pressure.
Episodes of bleeding.
Show full eligibility criteria
NCT02851407
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Predicting Concussion Outcomes with Salivary miRNA

The purpose of this study is to identify changes in salivary micro ribosomal nucleic acid (miRNA) expression that are predictive of symptom duration and severity following mild traumatic brain injury (mTBI) in children. The primary endpoints of this study are as follows: 1) Characterization of brain-related miRNA in the saliva of 100 children with mTBI and 50 age- and gender-matched controls between the ages of five and twenty-one years. 2) Identification of a set of salivary miRNAs that is predictive of duration and severity of mTBI symptoms.
Stokes -jstokes@pennstatehealth.psu.edu
All
All
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
5 to 21 years of age
Seen in the Penn State Pediatric Concussion Clinic within 2 weeks of most recent concussion
Exclusion Criteria:
Does not speak english
Periodontal disease
Ongoing seizure disorder, or other neurologic disorder
Drug or alcohol dependency
clinical diagnosis of severe TBI
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

An Early Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab Antibody (Mpdl3280a) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors

A study to determine if atezolizumab is safe and effective for patients with solid tumors that have not responded to previous treatment.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Confirmed solid tumor of varying types which has not responded to previous treatment.
Age at beginning of study is less than 30 years.
Weighs at least 3 kilograms (6.6 pounds).
Disease that is measurable based on accepted standards.
Tumor tissue from past surgery is available or willingness to have a biopsy prior to enrollment.
Exclusion Criteria:
Known brain tumor.
Patients with lymphoma, or other related diseases.
Treatment with high-dose chemotherapy and hematopoietic stem-cell rescue within a certain period of starting the study drug.
Prior stem-cell transplantation or prior solid-organ transplant.
Show full eligibility criteria
NCT02541604
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

A study of DFMO for patients with neuroblastoma in remission.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
A confirmed diagnosis of neuroblastoma.
Must be in complete remission (CR).
Tests and scans will be required to confirm remission.
Exclusion Criteria:
Patients below the defined minimum of height and weight.
Patients who are currently receiving another study drug may not participate.
Patients who are currently receiving other anticancer agents may not participate.
Show full eligibility criteria
NCT02679144
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Attitudes Toward Exercise, Nutrition, and Health

The purpose of this study is to evaluate the effectiveness of our Run for Fun program in changing attitudes of parents and children toward exercise, nutrition, and health. We plan to accomplish this through a 50 item survey administered at the beginning and end of the program.
Brady-Olympia -jbradyolympia@pennstatehealth.psu.edu
All
Younger than 18 year(s) old
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
5-12 years old
Fluent in english
parent willing to give permission
Exclusion Criteria:
Non-ambulatory children
Children without transportation to the Penn State Hershey Medical Center
Cognitive impairment
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Pubertal Influences on Social Brain Development

Understand how both behavior and brain reorganize to accommodate the changes that take place during adolescence.
Scherf -kss23@psu.edu
All
All
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
free of neurologic and endocrinology disorders currently and in the past on the basis of a health history obtained with a questionnaire
free of psychiatric disorders currently and in the past on the basis of a semi-structured interview
have a negative family history in first degree relatives of autism spectrum disorders
have no history of loss of consciousness
have no sensory impairments such as vision or hearing loss
Exclusion Criteria:
are a non-native English Speaker or non-English speaking or illerterate
have irremovable metallic foreign objects in the body (e.g., braces, cardiac pacemaker, aneurysm clip, cochlear implants, Intra Uterine Device, shrapnel, neurostimulators, defibrillator, artificial heart valve),
a questionable history of working with or around metal or metallic fragments in eyes or elsewhere in the body
are pregnant,
weight more than 250 lbs or get claustrophobic in small spaces
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Improving Autism Screening with Brain-Related miRNA

The central aim of this project is to characterize the expression of exosomal microRNA (miRNA) in children with autism spectrum disorder (ASD). We propose to measure the expression of extracellular miRNA in children with ASD. Expression levels of miRNA from blood and saliva will be compared between children with autism and normally developing controls. The goal of this study will be to identify genetic regulatory mechanisms involved in ASD and provide potential biomarkers for diagnostic screening.
Vallati -jvallati@pennstatehealth.psu.edu
All
Younger than 18 year(s) old
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Age: 24 Months
•6 Years
Confirmed Diagnosis of Autism or Developmental Delay or Healthy Child
Exclusion Criteria:
Wards of the state
Underlying Seizure Disorder
Underlying Genetic Disorder
Show full eligibility criteria
NCT02712853
  Email this study information to me
  Contact the study team
  See more information

Development of a caregiver-report instrument to assess child behavior.

It is commonly agreed that school-aged children display observable attachment behavior, although it is difficult to elicit in laboratory tasks. However, caregivers will observe this behavior on a regular basis when it occurs and can provide useful information regarding the structure and function of that behavior. The goal of the current proposal is to define a potential caregiver-reported instrument assessing early school-age children’s attachment behavior and collect initial data sufficient to examine the factor structure and reliability of the measure. Data collection will utilize anonymous online survey methodology and recruit through schools and preschools.
Allen -ballen1@pennstatehealth.psu.edu
All
All
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Adult caregiver of a child between the ages of 4 and 8
Adult caregiver is at least 18 years of age
Adult caregiver is the primary caregiver of the child.
Exclusion Criteria:
Child has an autism spectrum disorder, intellectual disability, or other developmental delay.
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team

A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

A study of the safety and efficacy of pazopanib for pediatric patients with solid tumors not responding to treatment.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Must be at least 1 year old and less than or equal to 18 years old when beginning the study.
A confirmed solid tumor of varying types.
Disease must have returned or is not responding to therapy.
Disease must be measurable by standard tests.
Must pass organ function and other tests.
Exclusion Criteria:
Female patients who are pregnant or breast-feeding are not eligible.
Patients who are currently receiving another study drug are not eligible.
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible.
Patients who are unable to swallow tablets or liquid are not eligible.
Show full eligibility criteria
NCT01956669
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Emerging relations between attention and negative affect in the first two years of life

The CAT Lab focuses on the ways in which emotion and attention interact to shape how children navigate through their social world. We do this through questionnaires and observations of behavior in our laboratory. This particular study will examine how children respond to emotional and social events. We ask infants and their parents to visit our lab 5 times, each visit being 4-6 months apart and usually lasting a little over an hour. During each visit to our lab, we ask infants to look at pictures of people and animals on a computer monitor while we record where their eyes are looking on the screen. Children also participate in several different games and play with different toys (just like those found in a common household such as balls, puppets, plastic animals, etc.). Some of these activities involve parents and some do not, but we do ask parents to stay in the room with their child for the full visit. During visits 2-5, we would also like to collect electroencephalogram (EEG) and respiratory sinus arrhythmia (RSA) data from your child. EEG measures the electrical activity in the brain using small metal sensors placed on the head with gel. RSA measures heart rate and breathing by placing small sensors on the torso. These procedures do not hurt, are low-risk, and provide real-time measurement of your child’s autonomic nervous system signals, much like an arm cuff measures blood pressure. When the sensors are removed, some children may feel like a bandage is being pulled off.
Promagan -nup21@psu.edu
All
Younger than 18 year(s) old
This study is also accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
infant is 4-months of age
infant born within +/- 3 weeks of due date
Infants without any serious medical complications
Infants of a healthy birth weight (>2500g; >5 lbs, 8 oz.)
Exclusion Criteria:
infant older or younger than 4 months of age
infant not of healthy gestational age
infants <2500g; <5lbs, 8 oz at birth
Infants who experienced any serious medical complications
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 2 locations

Study Locations

Hide all locations
Location
Harrisburg, PA
State College, PA

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers

Molecular-guided therapy for childhood cancer that has returned or is not responding to previous therapy.
Treadway, MS, RN, CCRP -streadway@pennstatehealth.psu.edu
All
All
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
A diagnosis of pediatric cancer of varying types for which there is no known cure or disease that is not responding to treatment.
Must be over one year of age at enrollment.
Must be less than or equal to 21 years at initial diagnosis.
Must have measurable disease by accepted standards.
Tumor must be accessible for biopsy.
Exclusion Criteria:
Has received chemotherapy within the last 7 days of biopsy.
Has received any radiotherapy to the primary sample site within the last 14 days.
Currently taking any other study drug.
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA